Yuan Sui is a NOMIS Center Postdoctoral Fellow at the Salk Institute for Biological Studies (La Jolla, US).

Originally from China, Sui earned his BS in Bioengineering from Jilin Agricultural University (China). His commitment to research led him to serve as a research volunteer and later a research assistant at Jilin University, where he focused on PTPN12 in non-small lung cancer. He furthered his academic journey by attaining a doctoral degree from the University of Oklahoma Health Sciences Center (US), specializing in biomedical sciences within the Pathology Department. His doctoral research primarily focused on investigating the role of DNPH1 in the development and tumorigenesis of melanoma. Notably, Sui received the prestigious Presbyterian Health Foundation (PHF) Research Support Grant to bolster his dissertation research. Additionally, he actively contributed to Inventory Disclosure No. 2023-003 titled “DNPH1 mice and drug resistance,” presented to the Office of Technology Development at the University of Oklahoma Health Sciences Center.

In his role as a NOMIS Fellow, Sui is channeling his extensive expertise into cancer research, with a specific emphasis on deciphering the influence of cytokine-induced alterations in the tumor microenvironment on pancreatic ductal adenocarcinoma (PDAC). His investigations will primarily revolve around oncostatin M (OSM) and its receptor (OSMR), exploring their roles in both early stages (pancreatitis) and later stages (tumor microenvironment) of PDAC development. Sui’s research is centered on understanding the capacity of OSM and OSMR to modulate inflammatory responses within tumors, both in vivo and in vitro. His ultimate objective is to unveil the critical significance of the OSM–OSMR axis in the initiation and progression of PDAC, potentially paving the way for novel therapeutic targets in this challenging disease.